Zaditen

Ketotifen Fumarate

Method of action: Antiallergic, Anti-Asthmatic, Antihistamines For Systemic Use, Membrane Stabilizing, Ophthalmologic Agent, Ophthalmologicals

Treatment option: Allergic Conjunctivitis, Pink Eye, Seasonal Allergic Conjunctivitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zaditen

Property	Description
Active ingredient	Ketotifen fumarate
Primary Forms	Oral, Ophthalmic solution
Pharmacological Class	H1-receptor antagonist, Mast cell stabilizer
General Purpose	Long-term protective anti-allergic support
Origin	Synthetic compound

Defining the Medicinal Entity: Ketotifen Fumarate

The core chemical entity of Zaditen is Ketotifen fumarate, a synthetic compound that functions as a dual-action agent. Its classification defines it both as a non-competitive H1-receptor antagonist and a mast cell stabilizer. This dual action provides a foundational approach to allergy management by reinforcing cellular defenses in addition to blocking the immediate allergic response.

Forms and Composition of Ketotifen Fumarate

Ketotifen fumarate is incorporated into distinct pharmaceutical preparations, allowing for both systemic and topical administration. Available dosage forms include oral capsules, tablets, and oral solution for systemic use, and ophthalmic solution (eye drops) for topical application. This variability in form permits the substance to be positioned for either internal use or localized treatment, such as for seasonal allergic conjunctivitis. The composition centers on the single active substance, Ketotifen fumarate, contained within either an aqueous vehicle for solutions or solid excipients for the oral capsule and tablet forms.

General Purpose of this Anti-Allergy Compound

The general purpose of this synthetic anti-allergic compound is to provide protective support for allergic conditions. By intervening early in the inflammatory cycle, the medicine’s unique dual action helps reduce the body's overall hyper-reactivity to allergens. This capacity to both block immediate chemical effects and prevent long-term cellular triggers supports the continuous management and relief of chronic allergic symptoms.

What side effects are possible with Zaditen?

Possible side effects and safety information

The official safety profile of Ketotifen fumarate, the active substance in Zaditen, is organized by regulatory bodies to classify potential adverse reactions based on frequency and the physiological system affected.

Frequency-Classified Adverse Reactions (Oral Formulation)

Adverse reactions are classified according to incidence rates documented in official regulatory labeling:

Common: Adverse effects reported frequently include somnolence (drowsiness) and manifestations of CNS stimulation, such as agitation, irritability, insomnia, and nervousness. Somnolence is often dose-related.
Uncommon: Effects reported less frequently include dizziness and dry mouth.
Very Rare: Severe cutaneous adverse reactions, specifically Erythema multiforme and Stevens-Johnson syndrome, are documented but occur infrequently.

Adverse effects such as somnolence, dizziness, and dry mouth are noted as transient; they may occur at the beginning of treatment but typically diminish with continued administration. For the ophthalmic solution, common reports include conjunctival hyperemia (eye redness) and headache.

Safety Considerations and Restrictions

The regulatory safety profile includes specific limitations and warnings:

Contraindications: Use of the systemic formulation is contraindicated with oral antidiabetic agents due to the reported risk of reversible thrombocytopenia (reduced platelet count).
Seizure Threshold: Caution is required for individuals with a history of epilepsy or a predisposition to seizures, as the medicine may potentially lower the seizure threshold.
Population Notes: Symptoms of CNS stimulation are observed particularly in children. The oral formulation is also contraindicated during lactation.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Zaditen (ketotifen fumarate) may present with specific documented signs and symptoms that require immediate medical attention. Urgent medical help must be sought if an overdose is suspected; you must contact a healthcare professional or hospital emergency services immediately.

Documented overdose manifestations range from neurological symptoms like drowsiness (to severe sedation), confusion, disorientation, nystagmus, and headache. Severe outcomes cited in regulatory labeling include reversible coma and cardiovascular effects such as tachycardia (fast heart rate) and hypotension (low blood pressure).

The core management approach is entirely symptomatic and supportive, as no specific antidote is known. Procedures documented in regulatory texts may include considering gastric lavage or activated charcoal if ingestion was very recent. Due to potential cardiovascular instability, monitoring of the cardiovascular system is recommended, alongside observation for bradycardia and respiratory depression.

Population-specific overdose notes indicate that children are at increased risk for developing convulsions and hyperexcitability following an overdose. Overdose with the ophthalmic solution is noted as unlikely to cause these systemic symptoms.

Therapeutic Uses of Zaditen

Eases Symptomatic Discomfort from Allergic Reactions

Zaditen is used in situations involving certain distressing symptoms, and is applied in addressing symptoms related to heightened physiological activity, such as symptoms related to inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort and functional strain. It is applied across domains where short-term symptomatic assistance is needed, providing supportive relief when symptoms may interfere with routine activities, contributing to improved daily comfort.

Supportive Management for Disruptive Symptom Patterns

This medicine is commonly used to help manage groups of symptoms that may appear suddenly or intensify over time, particularly those linked to episodic or fluctuating manifestations. It may assist with maintaining a sense of stability by easing the overall symptom burden during periods of heightened symptoms. It is considered relevant in clinical settings where additional management of discomfort is required. It supports patients during episodes of heightened discomfort.

Assistance in Stabilizing Recurrent Symptom Episodes

Zaditen is considered relevant when supportive symptom management is appropriate for conditions involving recurrent or episodic manifestations. It contributes to easing the overall symptom load, which supports patients during periods of heightened discomfort and temporary functional strain.

Quick Fact: May assist with symptoms related to ocular discomfort

Regulatory References

NIH DailyMed product label

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zaditen — Official Regulatory Information

This section outlines the eligibility and non-eligibility rules for Zaditen (Ketotifen Fumarate) based strictly on authoritative government regulatory documents.

Populations for Whom Use is Forbidden (Contraindicated)

Contraindication	Formulation Affected	Regulatory Basis
Hypersensitivity	Oral & Ophthalmic	Absolute Contraindication
Epilepsy / Seizures	Oral Only	Absolute Contraindication
Oral Antidiabetic Agents	Oral Only	Concomitant Use Prohibited
Breastfeeding	Oral Only	Absolute Contraindication

Age and Life Stage Eligibility

Children Under 3 Years: Use is not established for both oral and ophthalmic formulations; safety and effectiveness have not been formally affirmed by regulators for this age group.
Children 3 Years and Older, Adults, and Geriatrics: Generally approved for use, with no dosage adjustment required for the ophthalmic formulation in older adults or those with hepatic or renal impairment.
Pregnancy: Safety has not been established in human pregnancy. Use is conditional and should only be considered if the clinical benefit to the mother clearly outweighs the potential risk to the fetus.
Lactation: Use is contraindicated with the oral formulation; however, the ophthalmic solution can be used as systemic absorption is minimal.

Regulatory documents use these classifications to formally define the authorized user population and exclusion criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish specific interaction patterns for the active substance, ketotifen fumarate, differing between its oral and ophthalmic forms.

Documented Drug-Drug and Drug-Substance Interactions

The profile includes a formal regulatory restriction regarding combination use for the oral form. The simultaneous administration of oral antidiabetic drugs (such as biguanides) and oral ketotifen is officially stated as a contraindication due to a documented risk of reversible thrombocytopenia.

A separate pharmacodynamic interaction is documented, stating that co-administration of the oral form with CNS depressants, other antihistamines, or alcohol may lead to the potentiation of effects, which can result in enhanced sedation or reduced alertness.

Interaction Type	Interacting Substance/Class	Official Constraint
Contraindicated Combination	Oral Antidiabetic Drugs (e.g., biguanides)	Avoid simultaneous administration
Potentiation (Pharmacodynamic)	CNS Depressants, Alcohol	Potential for enhanced effects

Administration Requirements and Population Notes

For the ophthalmic solution, the official labeling includes a timing-based rule: when used with other eye medications, a separation of at least five minutes must be maintained between administrations. Additionally, the drug’s systemic clearance is stated to be most likely reduced in patients with severe hepatic impairment, which raises the official possibility of drug accumulation in this population.

Mechanism of Action

H1 Receptor Blockade

This drug functions as an antagonist to the H1 histamine receptor, preventing histamine—a key inflammatory mediator—from binding and activating these sites. This immediate action reduces the localized increase in vascular permeability and sensory nerve stimulation.

Stabilization of Mast Cells

It also engages a distinct mechanism by acting as a stabilizer of the mast cell membrane. This action inhibits the degranulation process, thereby modulating the initial release of histamine, leukotrienes, and other inflammatory chemicals.

Dual Pathway Modulation

The combination of both receptor blockade and cell stabilization means the drug modulates the response at two crucial points: blocking the effect of mediators that are already released and modulating the source of new mediator release. This dual pathway interference results in the modulation of the overall physiological response to specific stimuli. This sustained mechanistic effect modulates the overall inflammatory pathway activation.

Dosage and Administration Information

The usage of Zaditen (ketotifen fumarate) is determined by specific administration instructions related to its two approved forms: systemic oral administration and topical ophthalmic application.

Oral Administration

For systemic use (tablets or solution), the standard adult regimen is 1 mg administered twice daily, once in the morning and once in the evening. The medication must be taken with food. The adult dosage may be increased to a maximum of 2 mg twice daily if required. The oral dose for children aged 6 months to 3 years is calculated based on body weight, at 0.05 mg/ kg twice daily. When discontinuing long-term oral treatment, the process must be conducted gradually over a period of two to four weeks, rather than stopping abruptly.

Ophthalmic Administration

For topical use (ophthalmic solution), the administration is 1 drop applied to the affected eye(s) twice a day, typically administered every 8 to 12 hours. A key procedural requirement is the removal of soft contact lenses before instillation. Lenses may only be reinserted 10 to 15 minutes after the drops have been administered. Furthermore, if other topical eye medications are used, a minimum interval of 5 minutes must be observed between Zaditen and the other application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zaditen

This section summarizes the official clinical research and regulatory evidence landscape for Zaditen (ketotifen fumarate). The findings describe group patterns observed in studies and provide context but not individual predictions. Study results reflect the specific conditions under which they were conducted. This overview does not provide clinical guidance or treatment recommendations.

Evidence for Topical Use: Allergic Conjunctivitis

Research examining the eye drop formulation primarily focuses on short-term symptom changes related to acute allergic eye discomfort. These studies often take the form of Randomized Controlled Trials (RCTs), where the medicine was evaluated against a placebo, in research exploring how symptoms change over time. These trials included adults and children ge 3 years of age with a history of conditions associated with acute or disruptive episodes, such as seasonal allergic conjunctivitis.

Outcomes related to physical discomfort that were measured in this research included changes in scores for ocular itching and other outcomes linked to inflammatory or irritative states. Research reported patterns observed in the studies, including measurements of ocular itching scores during the study period. Further research explored the onset and duration of the reported ocular effect following a single topical application.

Evidence for Oral Prophylactic Use: Chronic Allergic Symptoms

Research explored the use of the oral forms of Zaditen in a prophylactic (preventive) role for conditions characterized by fluctuating or episodic manifestations, historically focusing on the supportive management of mild atopic asthma and other chronic allergic symptom patterns. Studies monitored outcomes in observed populations, particularly children in various age groups, over defined time intervals.

Outcomes studied related to systemic or functional imbalance included measuring changes in the frequency and severity of asthma attacks and monitoring whether patients reported a change in the requirement for concomitant anti-asthmatic medications. Research describes patterns related to these outcomes, often reporting that measurements were recorded after a minimum of 10 to 12 weeks of continuous administration. The evidence contributes to understanding symptom patterns as a supportive, add-on management option during periods of heightened symptom activity.

Research Gaps and Areas of Uncertainty

The research landscape reflects different follow-up durations for the topical and oral forms. For many core efficacy studies, the follow-up durations were limited, meaning there is limited information for long-term outcomes extending beyond six months to a year. While research describes patterns related to symptom control, comparative evidence with newer standard-of-care treatments for the oral formulation is often lacking in current high-quality RCTs. The results apply only to the specific populations studied, and data for certain comorbidity groups remain insufficient.

Key Studies & References Ketotifen Fumarate Capsule - Full Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Zaditen (FAQ)

Q: How quickly does Zaditen start working after you take it?

According to official product information, the different forms of Zaditen have different onsets of action. For the eye drop formulation, the anti-allergic effect is typically rapid, often observed within minutes of application. The full therapeutic benefit of the oral form is generally achieved after a period of regular use, although regulatory documents note that increasing the standard adult dose is one factor that may contribute to a quicker onset of efficacy.

Q: Do you need to take Zaditen every day for it to be effective?

Regulatory documents classify the oral form of this medicine as a prophylactic (preventive) agent that is not effective for treating sudden, acute symptoms. Official product information suggests that because it acts as a preventive agent, consistent, regular administration is necessary to achieve its intended long-term symptom management effects.

Q: Are there any common foods or drinks that interact with Zaditen?

Official administration instructions state that the oral tablets should be taken with food, although this does not significantly influence how the medicine works. Additionally, regulatory warnings advise patients to avoid consuming alcoholic drinks while using Zaditen because of the potential for enhanced side effects.

Q: Do you gain weight when using Zaditen long-term?

Regulatory documents list weight increase as a possible, but rare, side effect for the oral formulation. Based on official safety data, this means it is reported to affect fewer than 1 of every 1,000 patients.

Q: How long does Zaditen stay in your system?

After taking the oral form, the active substance is cleared from the body in two phases. Official pharmacokinetic data indicate that the terminal half-life—the time it takes for half the drug to be eliminated—is approximately 21 hours.

Q: How does Zaditen affect liver function?

Regulatory information notes that if a person has severe hepatic (liver) impairment, the body’s ability to clear the drug from the system is most likely reduced. This raises the official possibility of the drug accumulating in the body.

Q: Can Zaditen interact with medication for anxiety or depression?

Regulatory warnings indicate the potential for the effects of the drug to be potentiated (increased) when co-administered with certain central nervous system (CNS) depressants. This class includes sedatives and some medicines used for anxiety or depression.

Q: Is Zaditen available over the counter in some countries?

Yes, the active ingredient, ketotifen fumarate, is available in an Over-The-Counter (OTC) ophthalmic solution in the United States and other regions for the temporary relief of allergic eye itching. The oral form is typically available by prescription.

Q: Can Zaditen cause changes in mood?

Official regulatory safety data lists several CNS (central nervous system) stimulation symptoms as common side effects of the oral formulation. These effects, which include agitation, irritability, nervousness, and insomnia, have been observed particularly in children.

Q: Are there generic versions of Zaditen available?

Yes, regulatory information confirms that the active ingredient, ketotifen fumarate, is available in generic formulations for both the oral tablets and the ophthalmic solution.

Q: Can Zaditen be crushed or split if it's a tablet?

Official administration instructions for the oral tablets state that they must be swallowed whole. For children or others who may have difficulty swallowing tablets, an oral liquid solution is available.

Q: Does Zaditen help reduce swelling from allergic reactions?

The mechanism of action described in official texts includes blocking the H1-receptor to reduce a process called vascular permeability. This is a physiological change associated with the development of swelling.

Q: How often do people need to adjust their Zaditen dosage?

The standard adult dose for the oral formulation is 1 mg twice daily, but official documents state that the dose may be increased up to a maximum of 2 mg twice daily if necessary. The frequency and necessity of any dose adjustment are not specified in general regulatory guidance and depend on clinical evaluation.

Q: What happens if I accidentally miss a dose of Zaditen?

Official guidance for the ophthalmic solution advises that if a dose is missed and it is nearly time for the next scheduled application, the missed dose should be skipped entirely. Never apply more than the prescribed amount. For oral tablets, specific instructions should be sought from the prescribing professional.

Q: What happens if you take Zaditen past its expiration date?

Official regulatory instructions clearly state that the medicine must not be used after the expiration date (EXP) that is printed on the packaging.

Q: Is Zaditen a maintenance drug or a rescue medicine?

Regulatory documents confirm that the oral formulation is intended for use as a prophylactic (preventive) and maintenance agent. It is specifically stated that it is not effective for the treatment of acute asthma attacks or immediate, severe allergic reactions.

How should Zaditen be stored and disposed of?

Storage and Disposal of Zaditen (Ketotifen)

The medicine's regulatory labeling defines mandatory conditions to maintain stability and prevent contamination.

Area	Official Requirement
Temperature	Oral tablets must not be stored above 25 C. Ophthalmic solution storage ranges from 4 C to 25 C. The medicine must be kept from freezing.
Stability	The multi-dose ophthalmic solution must be discarded four weeks after opening. Do not use if the solution changes color or becomes cloudy.
Handling	Keep the container tightly closed. The dropper tip must not touch any surface. Oral tablets should remain in their original foil packaging until use.
Disposal	The medicine must be kept out of the sight and reach of children. Do not throw unused or expired Zaditen away via wastewater or household waste. You must consult a pharmacist for guidance on proper disposal, as these measures help protect the environment.